geocappy, BetaBodies have the advantage of being smaller molecules (they have a binding stage less) and therefore have additional applications. Most importantly Blood-Brain barrier applications are size sensitive. Their binding instance will be HIGHER hence they should be more effective. That is a statistical matter.
Because BB do not need the environment of blood they may play roles in applications that do, i'll call it, enveloped-cell access (entering the cell under false pretences as do viruses camouflaging themselves with an envelope that makes the cell believe they are another substance. The receptors that are a protein assisted cell entry system will then pull them in.
And since BB do not need the blood (there isn't any inside cells) they can bind the phophatidylserine (PS° while it is still inside the cell (before flipase makes it flip). There is much more research needed because you actually do not want that for cells in normal appotosys (natural cell death cycle). However BB are immediately ready for at least the same applications as bavituximab.
The patents for BB last longer too. Yet Bavi is far from played out as a 7 year extension will no doubt be granted on the related patents as there is NO commercial application based on them and the delay to market is due to FDA regulation which is on the list of reasons why extensions may be granted.
As for Ronin, I think he is mainly after the more recent shareholders hoping they will be in for a quicker buck and don't have the knowledge or expectations of shareholders that understand the language.
Technically, if the shareholders proposition date-lines are past, and possibly even were past when Ronin filed, there is no change to expect in the BoD. The CA of 27th July only requests an extra BoD member when Bavituximab gets approved. If PPHM would (speculation on non clear statement at last Q/CC) split the company in Avid and PS-targeting, then whatever verdict is reach may simply not carry to at least ONE of both parts. if there is ANY intentional action by PPHM here the AVid will remain the Peregrine of today and the new company will hold PS-targeting but will NOT be subject to the verdict.
And so we can go on for ages. But we should be shareholders of BOTH.
Peregrine Pharmaceuticals the Microsoft of Biotechnology! All In My Opinion. I am not advising anything, nor accusing anyone.
